294 related articles for article (PubMed ID: 10179303)
1. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
[TBL] [Abstract][Full Text] [Related]
2. Current good manufacturing practice for positron emission tomography drugs.
Food and Drug Administration, HHS
Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
[TBL] [Abstract][Full Text] [Related]
3. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
[TBL] [Abstract][Full Text] [Related]
4. Removal of regulations regarding certification of antibiotic drugs; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 May; 63(91):26127-9. PubMed ID: 10179335
[TBL] [Abstract][Full Text] [Related]
5. Investigational new drug applications; clinical holds--FDA. Direct final rule.
Fed Regist; 1998 Dec; 63(239):68676-8. PubMed ID: 10187558
[TBL] [Abstract][Full Text] [Related]
6. Removal of regulations regarding certification of drugs composed wholly or partly of insulin--FDA. Direct final rule.
Fed Regist; 1998 May; 63(92):26694-9. PubMed ID: 10179341
[TBL] [Abstract][Full Text] [Related]
7. Removal of regulations regarding certification of drugs composed wholly or partly of insulin; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 May; 63(92):26690-3. PubMed ID: 10179340
[TBL] [Abstract][Full Text] [Related]
8. Investigational new drug applications; clinical holds; companion document to direct final rule--FDA. Proposed rule.
Fed Regist; 1998 Dec; 63(239):68710-2. PubMed ID: 10187560
[TBL] [Abstract][Full Text] [Related]
9. Instrumentation and radiopharmaceutical validation.
Zigler SS
Q J Nucl Med Mol Imaging; 2009 Aug; 53(4):402-10. PubMed ID: 19834450
[TBL] [Abstract][Full Text] [Related]
10. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
Harapanhalli RS
Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
[TBL] [Abstract][Full Text] [Related]
11. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring; extension of comment period--FDA. Proposed rule; extension of comment period.
Fed Regist; 1998 Aug; 63(148):41219-20. PubMed ID: 10181522
[TBL] [Abstract][Full Text] [Related]
12. Removal of regulations regarding certification of antibiotic drugs--FDA. Direct final rule.
Fed Regist; 1998 May; 63(91):26066-9. PubMed ID: 10179333
[TBL] [Abstract][Full Text] [Related]
13. Digoxin products for oral use; revocation of conditions for marketing. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2002 Jun; 67(123):42992-7. PubMed ID: 12120661
[TBL] [Abstract][Full Text] [Related]
14. Medical devices; 30-day notices and 135-day PMA (premarket approval application) supplement review--FDA. Direct final rule.
Fed Regist; 1998 Apr; 63(80 Pt 1):20530-3. PubMed ID: 10179319
[TBL] [Abstract][Full Text] [Related]
15. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
[TBL] [Abstract][Full Text] [Related]
16. Operation of a radiopharmacy for a clinical trial.
Norenberg JP; Petry NA; Schwarz S
Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
[TBL] [Abstract][Full Text] [Related]
17. Current good manufacturing practice regulation and investigational new drugs. Direct final rule.
Food and Drug Administration. HHS
Fed Regist; 2006 Jan; 71(10):2458-62. PubMed ID: 16479693
[TBL] [Abstract][Full Text] [Related]
18. Medical devices; 30-day notices and 135-day PMA supplement review--FDA. Direct final rule; withdrawal.
Fed Regist; 1998 Aug; 63(154):42699. PubMed ID: 10182563
[TBL] [Abstract][Full Text] [Related]
19. Medical devices; reports of corrections and removals--FDA. Direct final rule.
Fed Regist; 1998 Aug; 63(152):42229-33. PubMed ID: 10181725
[TBL] [Abstract][Full Text] [Related]
20. Draft guidance for industry on developing medical imaging drugs and biologics; availability--FDA. Availability of guidance.
Fed Regist; 1998 Oct; 63(198):55067-9. PubMed ID: 10185833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
